Ponatinib in patients with refractory acute myeloid leukaemia: Findings from a phase 1 study

Neil P. Shah, Moshe Talpaz, Michael W.N. Deininger, Michael J. Mauro, Ian W. Flinn, Dale Bixby, Stephanie Lustgarten, Joseph M. Gozgit, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Hagop Kantarjian, Jorge E. Cortes

Research output: Contribution to journalLetter

40 Scopus citations
Original languageEnglish (US)
Pages (from-to)548-552
Number of pages5
JournalBritish Journal of Haematology
Volume162
Issue number4
DOIs
StatePublished - Aug 2013

Keywords

  • Acute myeloid leukaemia
  • FLT3 internal tandem duplications
  • FMS-like tyrosine kinase-3
  • Ponatinib
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Shah, N. P., Talpaz, M., Deininger, M. W. N., Mauro, M. J., Flinn, I. W., Bixby, D., Lustgarten, S., Gozgit, J. M., Clackson, T., Turner, C. D., Haluska, F. G., Kantarjian, H., & Cortes, J. E. (2013). Ponatinib in patients with refractory acute myeloid leukaemia: Findings from a phase 1 study. British Journal of Haematology, 162(4), 548-552. https://doi.org/10.1111/bjh.12382